New WHO Director Tedros’s Opening Vision: People First 04/07/2017 William New Tedros Adhanom Ghebreyesus began his first week as director-general of the UN World Health Organization by addressing the WHO staff with his vision for the organisation and the world. Top of the list? Humanity. Continue reading -> WHO Starts Work On Essential List Of Diagnostics To Facilitate Access, Lower Prices 16/06/2017 Catherine Saez The World Health Organization announced yesterday that it has begun work on a list of essential diagnostics, as an echo of its Model List of Essential Medicines. Continue reading -> WHO Director-Elect Tedros In US, Meeting With Funders, International Organisations, Governments 12/06/2017 William New World Health Organization Director-Elect Tedros Adhanom Ghebreyesus in touring the United States this week, visiting key funders of the WHO, partner international organisations, US government agencies and nongovernmental organisations, and a Canadian ministry. Continue reading -> WHO Members Take Steps Against Global Rise In Sales Of Human Body Parts 09/06/2017 Elise De Geyter The World Health Assembly last week adopted ten guiding ethical principles for the donation and management of medical products of human origin – that is, the rising market for body parts. Continue reading -> New WHO Essential Medicines List: Antibiotics, Hepatitis C, Leukaemia, TB 06/06/2017 Catherine Saez The World Health Organization's new list of essential medicines, those which should be available to everyone, anywhere, was issued today. To answer the rising concern about antimicrobial resistance, the antibiotics on the list have been divided in three groups, the last of which are to be used as a last resort. The list includes the first combination therapy to treat all six types of hepatitis C. However, no second line treatment for breast cancer has been added this year. Continue reading -> Shortage Of Affordable Insulin: Should WHO Extend Prequalification To Biosimilars? 10/05/2017 Tatum Anderson The WHO last week announced plans to explore options for prequalifying insulin, a process that already assesses the quality, safety and efficacy of medicinal products, such as tuberculosis and malaria drugs. The WHO is considering whether to extend the prequalification process to manufacturers creating me-too versions of insulins, more commonly known as biosimilars. Continue reading -> WHO Members Urged To Support Resolution Delinking Cancer Drug Prices From R&D Costs 04/05/2017 Catherine Saez A group of civil society organisations and health experts have sent a letter to delegates to this month’s annual World Health Assembly urging support for a study on the delinkage of the costs of research and development from the prices of cancer medicines. Member states reportedly met on the issue today and are still undecided. Continue reading -> Posts navigation Newer posts
WHO Starts Work On Essential List Of Diagnostics To Facilitate Access, Lower Prices 16/06/2017 Catherine Saez The World Health Organization announced yesterday that it has begun work on a list of essential diagnostics, as an echo of its Model List of Essential Medicines. Continue reading -> WHO Director-Elect Tedros In US, Meeting With Funders, International Organisations, Governments 12/06/2017 William New World Health Organization Director-Elect Tedros Adhanom Ghebreyesus in touring the United States this week, visiting key funders of the WHO, partner international organisations, US government agencies and nongovernmental organisations, and a Canadian ministry. Continue reading -> WHO Members Take Steps Against Global Rise In Sales Of Human Body Parts 09/06/2017 Elise De Geyter The World Health Assembly last week adopted ten guiding ethical principles for the donation and management of medical products of human origin – that is, the rising market for body parts. Continue reading -> New WHO Essential Medicines List: Antibiotics, Hepatitis C, Leukaemia, TB 06/06/2017 Catherine Saez The World Health Organization's new list of essential medicines, those which should be available to everyone, anywhere, was issued today. To answer the rising concern about antimicrobial resistance, the antibiotics on the list have been divided in three groups, the last of which are to be used as a last resort. The list includes the first combination therapy to treat all six types of hepatitis C. However, no second line treatment for breast cancer has been added this year. Continue reading -> Shortage Of Affordable Insulin: Should WHO Extend Prequalification To Biosimilars? 10/05/2017 Tatum Anderson The WHO last week announced plans to explore options for prequalifying insulin, a process that already assesses the quality, safety and efficacy of medicinal products, such as tuberculosis and malaria drugs. The WHO is considering whether to extend the prequalification process to manufacturers creating me-too versions of insulins, more commonly known as biosimilars. Continue reading -> WHO Members Urged To Support Resolution Delinking Cancer Drug Prices From R&D Costs 04/05/2017 Catherine Saez A group of civil society organisations and health experts have sent a letter to delegates to this month’s annual World Health Assembly urging support for a study on the delinkage of the costs of research and development from the prices of cancer medicines. Member states reportedly met on the issue today and are still undecided. Continue reading -> Posts navigation Newer posts
WHO Director-Elect Tedros In US, Meeting With Funders, International Organisations, Governments 12/06/2017 William New World Health Organization Director-Elect Tedros Adhanom Ghebreyesus in touring the United States this week, visiting key funders of the WHO, partner international organisations, US government agencies and nongovernmental organisations, and a Canadian ministry. Continue reading -> WHO Members Take Steps Against Global Rise In Sales Of Human Body Parts 09/06/2017 Elise De Geyter The World Health Assembly last week adopted ten guiding ethical principles for the donation and management of medical products of human origin – that is, the rising market for body parts. Continue reading -> New WHO Essential Medicines List: Antibiotics, Hepatitis C, Leukaemia, TB 06/06/2017 Catherine Saez The World Health Organization's new list of essential medicines, those which should be available to everyone, anywhere, was issued today. To answer the rising concern about antimicrobial resistance, the antibiotics on the list have been divided in three groups, the last of which are to be used as a last resort. The list includes the first combination therapy to treat all six types of hepatitis C. However, no second line treatment for breast cancer has been added this year. Continue reading -> Shortage Of Affordable Insulin: Should WHO Extend Prequalification To Biosimilars? 10/05/2017 Tatum Anderson The WHO last week announced plans to explore options for prequalifying insulin, a process that already assesses the quality, safety and efficacy of medicinal products, such as tuberculosis and malaria drugs. The WHO is considering whether to extend the prequalification process to manufacturers creating me-too versions of insulins, more commonly known as biosimilars. Continue reading -> WHO Members Urged To Support Resolution Delinking Cancer Drug Prices From R&D Costs 04/05/2017 Catherine Saez A group of civil society organisations and health experts have sent a letter to delegates to this month’s annual World Health Assembly urging support for a study on the delinkage of the costs of research and development from the prices of cancer medicines. Member states reportedly met on the issue today and are still undecided. Continue reading -> Posts navigation Newer posts
WHO Members Take Steps Against Global Rise In Sales Of Human Body Parts 09/06/2017 Elise De Geyter The World Health Assembly last week adopted ten guiding ethical principles for the donation and management of medical products of human origin – that is, the rising market for body parts. Continue reading -> New WHO Essential Medicines List: Antibiotics, Hepatitis C, Leukaemia, TB 06/06/2017 Catherine Saez The World Health Organization's new list of essential medicines, those which should be available to everyone, anywhere, was issued today. To answer the rising concern about antimicrobial resistance, the antibiotics on the list have been divided in three groups, the last of which are to be used as a last resort. The list includes the first combination therapy to treat all six types of hepatitis C. However, no second line treatment for breast cancer has been added this year. Continue reading -> Shortage Of Affordable Insulin: Should WHO Extend Prequalification To Biosimilars? 10/05/2017 Tatum Anderson The WHO last week announced plans to explore options for prequalifying insulin, a process that already assesses the quality, safety and efficacy of medicinal products, such as tuberculosis and malaria drugs. The WHO is considering whether to extend the prequalification process to manufacturers creating me-too versions of insulins, more commonly known as biosimilars. Continue reading -> WHO Members Urged To Support Resolution Delinking Cancer Drug Prices From R&D Costs 04/05/2017 Catherine Saez A group of civil society organisations and health experts have sent a letter to delegates to this month’s annual World Health Assembly urging support for a study on the delinkage of the costs of research and development from the prices of cancer medicines. Member states reportedly met on the issue today and are still undecided. Continue reading -> Posts navigation Newer posts
New WHO Essential Medicines List: Antibiotics, Hepatitis C, Leukaemia, TB 06/06/2017 Catherine Saez The World Health Organization's new list of essential medicines, those which should be available to everyone, anywhere, was issued today. To answer the rising concern about antimicrobial resistance, the antibiotics on the list have been divided in three groups, the last of which are to be used as a last resort. The list includes the first combination therapy to treat all six types of hepatitis C. However, no second line treatment for breast cancer has been added this year. Continue reading -> Shortage Of Affordable Insulin: Should WHO Extend Prequalification To Biosimilars? 10/05/2017 Tatum Anderson The WHO last week announced plans to explore options for prequalifying insulin, a process that already assesses the quality, safety and efficacy of medicinal products, such as tuberculosis and malaria drugs. The WHO is considering whether to extend the prequalification process to manufacturers creating me-too versions of insulins, more commonly known as biosimilars. Continue reading -> WHO Members Urged To Support Resolution Delinking Cancer Drug Prices From R&D Costs 04/05/2017 Catherine Saez A group of civil society organisations and health experts have sent a letter to delegates to this month’s annual World Health Assembly urging support for a study on the delinkage of the costs of research and development from the prices of cancer medicines. Member states reportedly met on the issue today and are still undecided. Continue reading -> Posts navigation Newer posts
Shortage Of Affordable Insulin: Should WHO Extend Prequalification To Biosimilars? 10/05/2017 Tatum Anderson The WHO last week announced plans to explore options for prequalifying insulin, a process that already assesses the quality, safety and efficacy of medicinal products, such as tuberculosis and malaria drugs. The WHO is considering whether to extend the prequalification process to manufacturers creating me-too versions of insulins, more commonly known as biosimilars. Continue reading -> WHO Members Urged To Support Resolution Delinking Cancer Drug Prices From R&D Costs 04/05/2017 Catherine Saez A group of civil society organisations and health experts have sent a letter to delegates to this month’s annual World Health Assembly urging support for a study on the delinkage of the costs of research and development from the prices of cancer medicines. Member states reportedly met on the issue today and are still undecided. Continue reading -> Posts navigation Newer posts
WHO Members Urged To Support Resolution Delinking Cancer Drug Prices From R&D Costs 04/05/2017 Catherine Saez A group of civil society organisations and health experts have sent a letter to delegates to this month’s annual World Health Assembly urging support for a study on the delinkage of the costs of research and development from the prices of cancer medicines. Member states reportedly met on the issue today and are still undecided. Continue reading -> Posts navigation Newer posts